Wealth Alliance’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$708K Sell
1,426
-120
-8% -$53.2K 0.06% 243
2026
Q1
$690K Sell
1,546
-19
-1% -$8.86K 0.07% 240
2025
Q4
$710K Buy
1,565
+306
+24% +$132K 0.07% 240
2025
Q3
$493K Buy
+1,259
New +$526K 0.05% 306
2024
Q1
Sell
-526
Closed -$214K 539
2023
Q4
$214K Buy
+526
New +$194K 0.03% 469

Other funds holding VRTX

Wealth Alliance's VRTX Position: Q2 2026 in Review

Wealth Alliance reduced its Vertex Pharmaceuticals (VRTX) stake by 7.8% in Q2 2026, selling an estimated $53.2K and leaving 1,426 shares worth $708K. The position accounts for 0.06% of the portfolio, ranked #243.

Wealth Alliance first reported a position in VRTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $710K in Q4 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Wealth Alliance held 1,426 shares of Vertex Pharmaceuticals worth $708K as of Q2 2026.
  • Wealth Alliance sold 120 Vertex Pharmaceuticals shares in Q2 2026, an estimated $53.2K.
  • Vertex Pharmaceuticals made up 0.06% of Wealth Alliance's portfolio in Q2 2026, its #243 holding.
  • Wealth Alliance first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • Wealth Alliance's Vertex Pharmaceuticals position peaked at $710K in Q4 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealth Alliance's 13F filing for Q2 2026, filed 11 Aug 2026.